Name:
HERTHENA-Lung02: Phase III clinical trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC following EGFR TKI therapy
Description:
HERTHENA-Lung02: Phase III clinical trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC following EGFR TKI therapy
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/123bc3bd-83dd-400f-b154-927ba3fe0943/videoscrubberimages/Scrubber_53.jpg
Duration:
T00H02M52S
Embed URL:
https://stream.cadmore.media/player/123bc3bd-83dd-400f-b154-927ba3fe0943
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/123bc3bd-83dd-400f-b154-927ba3fe0943/VJBM-2023-0013 Animation V7.mp4?sv=2019-02-02&sr=c&sig=fbQNc0UC9gAz177NZUWyOVVu%2F0ZIO%2FjuiRCsVhHGVk8%3D&st=2024-11-21T08%3A39%3A55Z&se=2024-11-21T10%3A44%3A55Z&sp=r
Upload Date:
2024-09-19T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
HER3-DXd, also known as patritumab deruxtecan, is an investigational antibody-drug conjugate composed of a fully human anti-HER3 monoclonal antibody, patritumab, linked to a topoisomerase I inhibitor.
In HERTHENA-Lung01, HER3-DXd demonstrated clinically meaningful efficacy in patients with advanced EGFR-mutated non-small cell lung cancer previously treated with an EGFR tyrosine kinase inhibitor therapy and platinum-based chemotherapy.
HERTHENA-Lung02 is a global, randomized, open-label, phase III trial that compares HER3-DXd to platinum-based chemotherapy in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer that has progressed on a third-generation EGFR tyrosine kinase inhibitor.
The patients included in the study are 18 years or older, have an ECOG performance status of 0 or 1, and are diagnosed with locally advanced or metastatic EGFR-mutated non-small cell lung cancer that progressed on treatment with third-generation EGFR-tyrosine kinase inhibitors.
Patients that had prior treatment with any agent containing a chemotherapeutic agent targeting topoisomerase I, anti-HER3 antibody, or systemic therapies (besides EGFR tyrosine kinase inhibitors), as well as those with severe respiratory and cardiovascular issues or active brain metastases are excluded.
This trial will evaluate the efficacy of HER3-DXd, based on progression-free survival and overall survival; its safety profile; patient-reported outcomes; and potential biomarkers of efficacy. This trial has study sites in many European and Asian countries, Australia, Canada and the United States.
The results of this trial could provide information about whether HER3-DXd provides potential therapeutic benefit for patients with advanced EGFR-mutated non-small cell lung cancer that is resistant to third-generation EGFR-tyrosine kinase inhibitors.
